(Medical Xpress) -- Mice genetically programmed to develop prostate cancer had smaller, slower growing tumors if they consumed a diet containing walnuts, UC Davis researchers report in the current issue of the British Journal of Nutrition.

A study published Online First in The Lancet has found that a common medication (dutasteride) used to treat enlargement of the prostate, may also reduce the need for treatments that pose risks of incontinence and impotence and delay growth of early-stage prostate cancer. Neil Fleshner, lead researcher of the ...

Dutasteride, a drug that is commonly used to treat enlargement of the prostate, might also slow the growth of early-stage prostate cancer and reduce the need for potentially debilitating treatments that carry risks of impotence and incontinence, according to an article published Online First in the Lancet.

Targeting a single protein can help fight both breast cancers and leukemias, according to two reports published online on January 23 in the Journal of Experimental Medicine.

SATURDAY, Jan. 21 (HealthDay News) -- Talking on a cellphone or texting while walking slows you down and makes it difficult to walk in a straight line, researchers report. Their preliminary research included 33 men and women in their 20s whose walking abilities were tested when they weren't using ...

According to a new U.S. Census Bureau report, the population of the United States is growing at its slowest rate in more than 70 years. The country's population increased by an estimated 2.8 million to 311.6 million from April 1, 2010 to July 1, 2011 says the report. The growth ...

Medicare spending growth is slowing, even as enrollment rises, The Washington Post reports. Meanwhile, several large Medicare Advantage plans turned a mighty profit in 2011, despite the volatility of the larger economy.

Developed countries and funding agencies are putting the brakes on growth in development assistance for health, raising the possibility that developing countries will have an even harder time meeting the Millennium Development Goal deadline looming in 2015, according to new research from the Institute for Health Metrics and Evaluation at ...

Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online ...

Treatment with dexpramipexole a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving ...

a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy – appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine. ...

(Massachusetts General Hospital) Results of a phase 2 clinical trial indicate that treatment with dexpramipexole -- a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy -- appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS).